Hospira to Handle Fill-Finish Operations for Genzyme's Multiple Drugs
Genzyme has signed a new supply agreement with Hospira Inc
Genzyme Corp (Cambridge, MA), which has been trying to resolve its manufacturing problems at its Allston Landing plant last June, has signed a new supply agreement with Hospira Inc (Lake Forest, Illinois) for fill-finish operations of seven products, according to a recent report by Reuters.
In May, Genzyme agreed to terms of a consent decree with the FDA, which requires the company to move its fill-finish operations out of the Allston Landing plant for Cerezyme, Fabrazyme, and Thyrogen, and Myozyme. Under the new agreement, Hospira will now also handle the fill-finish operations for Lumizyme, Thymoglobulin, Campath, and other products now being developed by Genzyme.
Under the terms of the consent decree Genzyme also will pay the government $175 million in profits from past sales of certain drugs.
Previous coverage:
Genzyme Expects $175 Million FineGenzyme to Exit Fill-Finish Operations at Allston Landing PlantFDA Takes Enforcement Action Regarding Genzyme's Allston Plant
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
